Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00094549 · ClinicalTrials.gov registry record · Phase 4
Olanzapine vs. Comparator and Placebo in the Treatment of Patients With Bipolar I Disorder
A Phase 4 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 500
- Enrollment target
NCT00094549: Completed Phase 4 study, sponsored by Eli Lilly and Company.
NCT00094549 is a Phase 4 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 500 participants, roughly in line with the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00094549, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 500 participants
- Enrollment target
Study Summary
The goals of this study are: A. To determine whether olanzapine can help patients with bipolar disorder who currently have mild to moderate mania. B. To assess the safety of olanzapine and any side effects that might be associated with it, as well as the quality of life and functioning of patients treated with olanzapine. C. To assess how olanzapine compares to divalproex.
Interventions
- DRUG placebo
- DRUG olanzapine
- DRUG divalproex sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2004-10 |
| Est. Completion | 2006-12 |
| Phase | Phase 4 |
What the finished NCT00094549 record still lists
NCT00094549 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00094549 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00094549 about?
NCT00094549 is a clinical study titled "Olanzapine vs. Comparator and Placebo in the Treatment of Patients With Bipolar I Disorder". The goals of this study are: A. To determine whether olanzapine can help patients with bipolar disorder who currently have mild to moderate mania. B. To assess the safety of olanzapine and any side effects that might be associated with it, as well as the quality of life and functioning of patients...
What is the current status of trial NCT00094549?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 500 participants. The study started on 2004-10. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00094549?
The interventions under investigation include: placebo (DRUG), olanzapine (DRUG), divalproex sodium (DRUG).
Who is sponsoring clinical trial NCT00094549?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00094549's enrollment target sits among peer trials
500 165th of 2000 higher than 1,824 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia